Oligomerix
Dr. Jacobsen joined AstraZeneca, Neuroscience iMed as Senior Project Director in December 2012, from Proteostasis Therapeutics, a drug development startup, where he was Vice President, Head of Translational Biology Department for two years. He has extensive drug development experience in the pharmaceutical industry, with focus on neurodegeneration and the targeting of misfolded proteins, having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D, and Associate Director and Team Leader, Alzheime’s disease-Modifying Program at Wyeth Research. Prior to that, Dr.Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid. In addition, he serves on the Scientific Advisory Boards of several biotechnology startup organizations, and is adjunct Associate Professor at New York University School of Medicine.
This person is not in the org chart
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.